PortfoliosLab logoPortfoliosLab logo
CPRX vs. CL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CPRX vs. CL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Colgate-Palmolive Company (CL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CPRX achieves a 33.98% return, which is significantly higher than CL's 13.09% return. Over the past 10 years, CPRX has outperformed CL with an annualized return of 48.23%, while CL has yielded a comparatively lower 4.55% annualized return.


CPRX

1D
0.00%
1M
8.80%
YTD
33.98%
6M
38.24%
1Y
25.58%
3Y*
39.37%
5Y*
41.56%
10Y*
48.23%

CL

1D
-0.18%
1M
1.16%
YTD
13.09%
6M
13.38%
1Y
-1.55%
3Y*
7.61%
5Y*
3.44%
10Y*
4.55%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CPRX vs. CL - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CPRX
Catalyst Pharmaceuticals, Inc.
33.98%11.84%24.15%-9.62%174.74%102.69%-10.93%95.31%-50.90%272.38%
CL
Colgate-Palmolive Company
13.09%-10.98%16.57%3.78%-5.44%2.08%27.17%18.60%-19.19%17.88%

Correlation

The correlation between CPRX and CL is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (10Y)
Calculated over the trailing 10-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Nov 9, 2006

0.08

Fundamentals

Market Cap

CPRX:

$3.97B

CL:

$71.07B

EPS

CPRX:

$1.74

CL:

$2.58

PE Ratio

CPRX:

17.97

CL:

34.22

PEG Ratio

CPRX:

0.32

CL:

8.84

PS Ratio

CPRX:

6.66

CL:

3.43

PB Ratio

CPRX:

3.92

CL:

490.11

Total Revenue (TTM)

CPRX:

$596.96M

CL:

$20.80B

Gross Profit (TTM)

CPRX:

$378.23M

CL:

$12.49B

EBITDA (TTM)

CPRX:

$313.50M

CL:

$3.92B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CPRX vs. CL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX
CPRX Risk / Return Rank: 6060
Overall Rank
CPRX Sharpe Ratio Rank: 6464
Sharpe Ratio Rank
CPRX Sortino Ratio Rank: 5959
Sortino Ratio Rank
CPRX Omega Ratio Rank: 5959
Omega Ratio Rank
CPRX Calmar Ratio Rank: 6060
Calmar Ratio Rank
CPRX Martin Ratio Rank: 5757
Martin Ratio Rank

CL
CL Risk / Return Rank: 3434
Overall Rank
CL Sharpe Ratio Rank: 3737
Sharpe Ratio Rank
CL Sortino Ratio Rank: 3131
Sortino Ratio Rank
CL Omega Ratio Rank: 3030
Omega Ratio Rank
CL Calmar Ratio Rank: 3535
Calmar Ratio Rank
CL Martin Ratio Rank: 3636
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. CL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Colgate-Palmolive Company (CL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CPRXCLDifference

Sharpe ratio

Return per unit of total volatility

0.76

-0.08

+0.84

Sortino ratio

Return per unit of downside risk

1.25

0.04

+1.21

Omega ratio

Gain probability vs. loss probability

1.16

1.00

+0.16

Calmar ratio

Return relative to maximum drawdown

0.93

-0.14

+1.07

Martin ratio

Return relative to average drawdown

1.69

-0.23

+1.93

CPRX vs. CL - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.76, which is higher than the CL Sharpe Ratio of -0.08. The chart below compares the historical Sharpe Ratios of CPRX and CL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


CPRXCLDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.76

-0.08

+0.84

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.87

0.19

+0.69

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.80

0.23

+0.57

Sharpe Ratio (All Time)

Calculated using the full available price history

0.09

0.43

-0.34

Drawdowns

CPRX vs. CL - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, which is greater than CL's maximum drawdown of -58.91%. Use the drawdown chart below to compare losses from any high point for CPRX and CL.


Loading charts...

Drawdown Indicators


CPRXCLDifference

Max Drawdown

Largest peak-to-trough decline

-94.25%

-58.91%

-35.34%

Max Drawdown (1Y)

Largest decline over 1 year

-27.29%

-18.64%

-8.65%

Max Drawdown (3Y)

Largest decline over 3 years

-27.29%

-29.05%

+1.76%

Max Drawdown (5Y)

Largest decline over 5 years

-45.37%

-29.05%

-16.32%

Max Drawdown (10Y)

Largest decline over 10 years

-64.87%

-29.05%

-35.82%

Current Drawdown

Current decline from peak

-0.19%

-15.44%

+15.25%

Average Drawdown

Average peak-to-trough decline

-52.06%

-11.24%

-40.82%

Ulcer Index

Depth and duration of drawdowns from previous peaks

14.95%

11.18%

+3.77%

Volatility

CPRX vs. CL - Volatility Comparison

Catalyst Pharmaceuticals, Inc. (CPRX) has a higher volatility of 6.81% compared to Colgate-Palmolive Company (CL) at 5.52%. This indicates that CPRX's price experiences larger fluctuations and is considered to be riskier than CL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CPRXCLDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.81%

5.52%

+1.29%

Volatility (6M)

Calculated over the trailing 6-month period

23.82%

16.18%

+7.64%

Volatility (1Y)

Calculated over the trailing 1-year period

33.60%

20.77%

+12.83%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

47.86%

18.57%

+29.29%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.62%

19.64%

+40.98%

Dividends

CPRX vs. CL - Dividend Comparison

CPRX has not paid dividends to shareholders, while CL's dividend yield for the trailing twelve months is around 2.37%.


PositionTTM20252024202320222021202020192018201720162015
CL
Colgate-Palmolive Company
2.37%2.61%2.18%2.40%2.36%2.10%2.05%2.48%2.79%2.11%2.37%2.25%
CPRX
Catalyst Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

CPRX vs. CL - Financials Comparison

This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Colgate-Palmolive Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B20222023202420252026
149.39M
5.32B
(CPRX) Total Revenue
(CL) Total Revenue
Values in USD except per share items

CPRX vs. CL - Profitability Comparison

The chart below illustrates the profitability comparison between Catalyst Pharmaceuticals, Inc. and Colgate-Palmolive Company over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%202220232024202520260
60.6%
Portfolio components
CPRX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.

CL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported a gross profit of 3.23B and revenue of 5.32B. Therefore, the gross margin over that period was 60.6%.

CPRX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.

CL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported an operating income of 1.16B and revenue of 5.32B, resulting in an operating margin of 21.7%.

CPRX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.

CL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Colgate-Palmolive Company reported a net income of 646.00M and revenue of 5.32B, resulting in a net margin of 12.1%.


Frequently Asked Questions


CPRX and CL have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CPRX has higher volatility (6.81%) compared to CL (5.52%). In terms of maximum drawdown, CPRX dropped -94.25% vs CL's -58.91%.

CPRX currently has the higher Sharpe Ratio (0.76 vs -0.08), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CPRX and CL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer